Bionik Laboratories Corp.
BNKL · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $501 | $575 | $486 | $243 |
| % Growth | -12.9% | 18.3% | 100.2% | – |
| Cost of Goods Sold | $247 | $305 | $189 | $75 |
| Gross Profit | $254 | $271 | $298 | $168 |
| % Margin | 50.7% | 47% | 61.2% | 69% |
| R&D Expenses | $206 | $94 | $226 | $378 |
| G&A Expenses | $869 | $774 | $687 | $601 |
| SG&A Expenses | $1,346 | $1,220 | $1,183 | $1,163 |
| Sales & Mktg Exp. | $477 | $446 | $496 | $562 |
| Other Operating Expenses | -$5 | -$2 | -$1 | -$6 |
| Operating Expenses | $1,551 | $1,314 | $1,409 | $1,541 |
| Operating Income | -$1,297 | -$1,043 | -$1,111 | -$1,373 |
| % Margin | -258.8% | -181.4% | -228.5% | -565.5% |
| Other Income/Exp. Net | -$59 | -$33 | -$18 | -$11 |
| Pre-Tax Income | -$1,356 | -$1,076 | -$1,129 | -$1,384 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,415 | -$1,109 | -$1,148 | -$1,395 |
| % Margin | -282.5% | -192.9% | -236% | -574.5% |
| EPS | -0.2 | -0.16 | -0.17 | -0.2 |
| % Growth | -25% | 5.9% | 15% | – |
| EPS Diluted | -0.2 | -0.16 | -0.17 | -0.2 |
| Weighted Avg Shares Out | 6,968 | 6,880 | 6,880 | 6,880 |
| Weighted Avg Shares Out Dil | 6,968 | 6,880 | 6,880 | 6,880 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $54 | $30 | $17 | $5 |
| Depreciation & Amortization | $20 | $20 | $12 | $12 |
| EBITDA | -$1,282 | -$1,026 | -$1,100 | -$1,367 |
| % Margin | -255.9% | -178.4% | -226.2% | -563.1% |